Nationally funded clinical research centres embedded within major NHS teaching trusts are facing a combined reduction of up to £187 million from 2028, when the National Institute for Health and Care Research introduces new caps on the awards it makes to its network of Biomedical Research Centres across England.

The NIHR's 20 Biomedical Research Centres are partnerships between NHS trusts and universities that facilitate early-stage experimental medicine research and support the translation of scientific discoveries. The current funding round, the fourth of its kind, awarded nearly £800 million in total to support research across areas including cancer, mental health, dementia and infectious diseases. That money flows predominantly to a small number of large teaching trusts concentrated in London, Oxford and Cambridge, which host the most established centres.

The scale of the forthcoming reduction becomes clear when individual awards in the current cycle are compared against what will be permitted from April 2028. University College London Hospitals NHS Foundation Trust received £90.2 million for the 2022 to 2027 period, one of only two centres awarded over £90 million. Imperial College Healthcare NHS Trust was awarded £95.3 million for the same period. Manchester University NHS Foundation Trust received £64.1 million, which was described as the largest single research award given by the NIHR to the city region.

Under the rules for the next funding round, those figures will not be replicated. Eligible NHS organisations in England may submit one application for funding over five years from 1 April 2028 to 31 March 2033, and applications should request no more than £50 million. Funding above that level may be agreed only in exceptional circumstances, specifically where a centre can demonstrate it is actively building capacity in areas not currently served by early translational research infrastructure, and where additional money flows directly to those partner organisations rather than to the lead trust itself.

The practical consequence for trusts that have built their research programmes around substantially larger awards is considerable. A centre previously receiving £95 million and now capped at £50 million faces a reduction of £45 million over five years from that source alone. Across the network, those individual shortfalls aggregate to the £187 million figure.

BRC funding is used to create an environment where scientific endeavour can thrive, to attract senior talent, to support a critical mass of people and infrastructure focused on biomedical innovation, and to deliver early translational and experimental medicine research. In practice, that means funding dedicated research beds, laboratory equipment, the salaries of clinical academics who divide their time between treating patients and conducting trials, and the administrative infrastructure that allows a hospital to run early-phase studies that would not otherwise be commercially viable. Trust executives have argued that cuts to this stream threaten not only individual programmes but the UK's broader standing in life sciences at a time when the government has publicly committed to expanding commercial clinical trial activity.

Over the past nine years, BRCs have drawn in nearly £9 billion of funding from external organisations, collaborated with almost 3,000 small and medium-sized companies, generated more than 11,800 patents, and supported 85 spin-out companies, with intellectual property generating more than £800 million in revenue. That leverage ratio, external investment attracted relative to public funding committed, forms much of the case made by hospital leaders against steep reductions in base awards.

The NIHR's rationale for the new cap reflects a deliberate strategic choice rather than a simple budget constraint. The BRC funding opportunity is part of a broader £860 million package of translational infrastructure funding, which includes £600 million allocated specifically for BRCs and a further £260 million for new Strategic Infrastructure Partnerships intended to pull discoveries from early-phase research into wider clinical adoption. The intention, as set out by NIHR, is to distribute research capacity more evenly and require established centres to actively support institutions that cannot yet compete independently for major awards. The previous funding round already sought to shift the balance, with nearly £250 million ringfenced for organisations outside of London, Oxford and Cambridge.

Trusts facing the largest reductions will need to move quickly to offset the gap. Options include expanding their portfolio of commercially-sponsored clinical trials, pursuing research charity grants, and deepening partnerships with pharmaceutical companies under the government's Voluntary Branded Medicines Pricing, Access and Growth programme, which has already directed capital funding toward NHS research infrastructure. Whether those routes can fully replace the reduction in core NIHR awards within the timeline available remains a significant open question.

The NIHR is expected to open formal consultation on the new BRC competition in the coming months, giving trust leaders and academic partners a structured opportunity to contest or seek modifications to the terms before applications open. How far that process alters the £50 million cap will be watched closely by the institutions most exposed to the change.

‍